1 Market Overview

1.1 Product Overview and Scope of HER2-Positive Breast Cancer

1.2 Classification of HER2-Positive Breast Cancer by Type

1.2.1 Overview: Global HER2-Positive Breast Cancer Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global HER2-Positive Breast Cancer Revenue Market Share by Type in 2020

1.2.3 Grifola Frondosa

1.2.4 Surgery

1.2.5 Radiation and Chemotherapy

1.2.6 Endocrine Therapy

1.2.7 Molecular Targeted Therapy

1.3 Global HER2-Positive Breast Cancer Market by Application

1.3.1 Overview: Global HER2-Positive Breast Cancer Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Hospital

1.3.3 Specialist Clinic

1.3.4 Biotechnology and Pharmaceutical Companies

1.3.5 Research and Academic Institutions

1.3.6 Other

1.4 Global HER2-Positive Breast Cancer Market Size & Forecast

1.5 Global HER2-Positive Breast Cancer Market Size and Forecast by Region

1.5.1 Global HER2-Positive Breast Cancer Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global HER2-Positive Breast Cancer Market Size by Region, (2016-2021)

1.5.3 North America HER2-Positive Breast Cancer Market Size and Prospect (2016-2026)

1.5.4 Europe HER2-Positive Breast Cancer Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific HER2-Positive Breast Cancer Market Size and Prospect (2016-2026)

1.5.6 South America HER2-Positive Breast Cancer Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa HER2-Positive Breast Cancer Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 HER2-Positive Breast Cancer Market Drivers

1.6.2 HER2-Positive Breast Cancer Market Restraints

1.6.3 HER2-Positive Breast Cancer Trends Analysis

2 Company Profiles

2.1 Pfizer (Pharmacia and Upjohn Company)

2.1.1 Pfizer (Pharmacia and Upjohn Company) Details

2.1.2 Pfizer (Pharmacia and Upjohn Company) Major Business

2.1.3 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product and Solutions

2.1.4 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Pfizer (Pharmacia and Upjohn Company) Recent Developments and Future Plans

2.2 Novartis

2.2.1 Novartis Details

2.2.2 Novartis Major Business

2.2.3 Novartis HER2-Positive Breast Cancer Product and Solutions

2.2.4 Novartis HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Novartis Recent Developments and Future Plans

2.3 AstraZeneca Pharmaceuticals

2.3.1 AstraZeneca Pharmaceuticals Details

2.3.2 AstraZeneca Pharmaceuticals Major Business

2.3.3 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

2.3.4 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 AstraZeneca Pharmaceuticals Recent Developments and Future Plans

2.4 Eli Lilly

2.4.1 Eli Lilly Details

2.4.2 Eli Lilly Major Business

2.4.3 Eli Lilly HER2-Positive Breast Cancer Product and Solutions

2.4.4 Eli Lilly HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Eli Lilly Recent Developments and Future Plans

2.5 Roche Group

2.5.1 Roche Group Details

2.5.2 Roche Group Major Business

2.5.3 Roche Group HER2-Positive Breast Cancer Product and Solutions

2.5.4 Roche Group HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Roche Group Recent Developments and Future Plans

2.6 Merck

2.6.1 Merck Details

2.6.2 Merck Major Business

2.6.3 Merck HER2-Positive Breast Cancer Product and Solutions

2.6.4 Merck HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Merck Recent Developments and Future Plans

2.7 Jiangsu HengRui Medicine

2.7.1 Jiangsu HengRui Medicine Details

2.7.2 Jiangsu HengRui Medicine Major Business

2.7.3 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product and Solutions

2.7.4 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Jiangsu HengRui Medicine Recent Developments and Future Plans

2.8 Odonate Therapeutics

2.8.1 Odonate Therapeutics Details

2.8.2 Odonate Therapeutics Major Business

2.8.3 Odonate Therapeutics HER2-Positive Breast Cancer Product and Solutions

2.8.4 Odonate Therapeutics HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Odonate Therapeutics Recent Developments and Future Plans

2.9 Radius Pharmaceuticals

2.9.1 Radius Pharmaceuticals Details

2.9.2 Radius Pharmaceuticals Major Business

2.9.3 Radius Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

2.9.4 Radius Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Radius Pharmaceuticals Recent Developments and Future Plans

2.10 Immunomedics

2.10.1 Immunomedics Details

2.10.2 Immunomedics Major Business

2.10.3 Immunomedics HER2-Positive Breast Cancer Product and Solutions

2.10.4 Immunomedics HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Immunomedics Recent Developments and Future Plans

2.11 Syndax Pharmaceuticals

2.11.1 Syndax Pharmaceuticals Details

2.11.2 Syndax Pharmaceuticals Major Business

2.11.3 Syndax Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

2.11.4 Syndax Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 Syndax Pharmaceuticals Recent Developments and Future Plans

2.12 Bayer

2.12.1 Bayer Details

2.12.2 Bayer Major Business

2.12.3 Bayer HER2-Positive Breast Cancer Product and Solutions

2.12.4 Bayer HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.12.5 Bayer Recent Developments and Future Plans

2.13 Eagle Pharmaceuticals

2.13.1 Eagle Pharmaceuticals Details

2.13.2 Eagle Pharmaceuticals Major Business

2.13.3 Eagle Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

2.13.4 Eagle Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.13.5 Eagle Pharmaceuticals Recent Developments and Future Plans

2.14 Merrimack Pharmaceuticals

2.14.1 Merrimack Pharmaceuticals Details

2.14.2 Merrimack Pharmaceuticals Major Business

2.14.3 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

2.14.4 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.14.5 Merrimack Pharmaceuticals Recent Developments and Future Plans

2.15 GlaxoSmithKline

2.15.1 GlaxoSmithKline Details

2.15.2 GlaxoSmithKline Major Business

2.15.3 GlaxoSmithKline HER2-Positive Breast Cancer Product and Solutions

2.15.4 GlaxoSmithKline HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.15.5 GlaxoSmithKline Recent Developments and Future Plans

2.16 Millennium Pharmaceuticals

2.16.1 Millennium Pharmaceuticals Details

2.16.2 Millennium Pharmaceuticals Major Business

2.16.3 Millennium Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

2.16.4 Millennium Pharmaceuticals HER2-Positive Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)

2.16.5 Millennium Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global HER2-Positive Breast Cancer Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 HER2-Positive Breast Cancer Players Market Share

3.2.2 Top 10 HER2-Positive Breast Cancer Players Market Share

3.2.3 Market Competition Trend

3.3 HER2-Positive Breast Cancer Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global HER2-Positive Breast Cancer Revenue and Market Share by Type (2016-2021)

4.2 Global HER2-Positive Breast Cancer Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global HER2-Positive Breast Cancer Revenue Market Share by Application (2016-2021)

5.2 HER2-Positive Breast Cancer Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America HER2-Positive Breast Cancer Revenue by Type (2016-2026)

6.2 North America HER2-Positive Breast Cancer Revenue by Application (2016-2026)

6.3 North America HER2-Positive Breast Cancer Market Size by Country

6.3.1 North America HER2-Positive Breast Cancer Revenue by Country (2016-2026)

6.3.2 United States HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

6.3.3 Canada HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

6.3.4 Mexico HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe HER2-Positive Breast Cancer Revenue by Type (2016-2026)

7.2 Europe HER2-Positive Breast Cancer Revenue by Application (2016-2026)

7.3 Europe HER2-Positive Breast Cancer Market Size by Country

7.3.1 Europe HER2-Positive Breast Cancer Revenue by Country (2016-2026)

7.3.2 Germany HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

7.3.3 France HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

7.3.4 United Kingdom HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

7.3.5 Russia HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

7.3.6 Italy HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific HER2-Positive Breast Cancer Revenue by Type (2016-2026)

8.2 Asia-Pacific HER2-Positive Breast Cancer Revenue by Application (2016-2026)

8.3 Asia-Pacific HER2-Positive Breast Cancer Market Size by Region

8.3.1 Asia-Pacific HER2-Positive Breast Cancer Revenue by Region (2016-2026)

8.3.2 China HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

8.3.3 Japan HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

8.3.4 South Korea HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

8.3.5 India HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

8.3.7 Australia HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America HER2-Positive Breast Cancer Revenue by Type (2016-2026)

9.2 South America HER2-Positive Breast Cancer Revenue by Application (2016-2026)

9.3 South America HER2-Positive Breast Cancer Market Size by Country

9.3.1 South America HER2-Positive Breast Cancer Revenue by Country (2016-2026)

9.3.2 Brazil HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

9.3.3 Argentina HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa HER2-Positive Breast Cancer Revenue by Type (2016-2026)

10.2 Middle East & Africa HER2-Positive Breast Cancer Revenue by Application (2016-2026)

10.3 Middle East & Africa HER2-Positive Breast Cancer Market Size by Country

10.3.1 Middle East & Africa HER2-Positive Breast Cancer Revenue by Country (2016-2026)

10.3.2 Turkey HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

10.3.4 UAE HER2-Positive Breast Cancer Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global HER2-Positive Breast Cancer Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global HER2-Positive Breast Cancer Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market HER2-Positive Breast Cancer Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global HER2-Positive Breast Cancer Revenue (USD Million) by Region (2016-2021)

Table 5. Global HER2-Positive Breast Cancer Revenue Market Share by Region (2021-2026)

Table 6. Pfizer (Pharmacia and Upjohn Company) Corporate Information, Head Office, and Major Competitors

Table 7. Pfizer (Pharmacia and Upjohn Company) Major Business

Table 8. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product and Solutions

Table 9. Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Novartis Corporate Information, Head Office, and Major Competitors

Table 11. Novartis Major Business

Table 12. Novartis HER2-Positive Breast Cancer Product and Solutions

Table 13. Novartis HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. AstraZeneca Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 15. AstraZeneca Pharmaceuticals Major Business

Table 16. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

Table 17. AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Eli Lilly Corporate Information, Head Office, and Major Competitors

Table 19. Eli Lilly Major Business

Table 20. Eli Lilly HER2-Positive Breast Cancer Product and Solutions

Table 21. Eli Lilly HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Roche Group Corporate Information, Head Office, and Major Competitors

Table 23. Roche Group Major Business

Table 24. Roche Group HER2-Positive Breast Cancer Product and Solutions

Table 25. Roche Group HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Merck Corporate Information, Head Office, and Major Competitors

Table 27. Merck Major Business

Table 28. Merck HER2-Positive Breast Cancer Product and Solutions

Table 29. Merck HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Jiangsu HengRui Medicine Corporate Information, Head Office, and Major Competitors

Table 31. Jiangsu HengRui Medicine Major Business

Table 32. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product and Solutions

Table 33. Jiangsu HengRui Medicine HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Odonate Therapeutics Corporate Information, Head Office, and Major Competitors

Table 35. Odonate Therapeutics Major Business

Table 36. Odonate Therapeutics HER2-Positive Breast Cancer Product and Solutions

Table 37. Odonate Therapeutics HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Radius Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 39. Radius Pharmaceuticals Major Business

Table 40. Radius Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

Table 41. Radius Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Immunomedics Corporate Information, Head Office, and Major Competitors

Table 43. Immunomedics Major Business

Table 44. Immunomedics HER2-Positive Breast Cancer Product and Solutions

Table 45. Immunomedics HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Syndax Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 47. Syndax Pharmaceuticals Major Business

Table 48. Syndax Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

Table 49. Syndax Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Bayer Corporate Information, Head Office, and Major Competitors

Table 51. Bayer Major Business

Table 52. Bayer HER2-Positive Breast Cancer Product and Solutions

Table 53. Bayer HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 54. Eagle Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 55. Eagle Pharmaceuticals Major Business

Table 56. Eagle Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

Table 57. Eagle Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 58. Merrimack Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 59. Merrimack Pharmaceuticals Major Business

Table 60. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

Table 61. Merrimack Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 62. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors

Table 63. GlaxoSmithKline Major Business

Table 64. GlaxoSmithKline HER2-Positive Breast Cancer Product and Solutions

Table 65. GlaxoSmithKline HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 66. Millennium Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 67. Millennium Pharmaceuticals Major Business

Table 68. Millennium Pharmaceuticals HER2-Positive Breast Cancer Product and Solutions

Table 69. Millennium Pharmaceuticals HER2-Positive Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 70. Global HER2-Positive Breast Cancer Revenue (USD Million) by Players (2019-2021)

Table 71. Global HER2-Positive Breast Cancer Revenue Share by Players (2019-2021)

Table 72. Breakdown of HER2-Positive Breast Cancer by Company Type (Tier 1, Tier 2 and Tier 3)

Table 73. HER2-Positive Breast Cancer Players Head Office, Products and Services Provided

Table 74. HER2-Positive Breast Cancer Mergers & Acquisitions in the Past Five Years

Table 75. HER2-Positive Breast Cancer New Entrants and Expansion Plans

Table 76. Global HER2-Positive Breast Cancer Revenue (USD Million) by Type (2016-2021)

Table 77. Global HER2-Positive Breast Cancer Revenue Share by Type (2016-2021)

Table 78. Global HER2-Positive Breast Cancer Revenue Forecast by Type (2021-2026)

Table 79. Global HER2-Positive Breast Cancer Revenue by Application (2016-2021)

Table 80. Global HER2-Positive Breast Cancer Revenue Forecast by Application (2021-2026)

Table 81. North America HER2-Positive Breast Cancer Revenue by Type (2016-2021) & (USD Million)

Table 82. North America HER2-Positive Breast Cancer Revenue by Type (2021-2026) & (USD Million)

Table 83. North America HER2-Positive Breast Cancer Revenue by Application (2016-2021) & (USD Million)

Table 84. North America HER2-Positive Breast Cancer Revenue by Application (2021-2026) & (USD Million)

Table 85. North America HER2-Positive Breast Cancer Revenue by Country (2016-2021) & (USD Million)

Table 86. North America HER2-Positive Breast Cancer Revenue by Country (2021-2026) & (USD Million)

Table 87. Europe HER2-Positive Breast Cancer Revenue by Type (2016-2021) & (USD Million)

Table 88. Europe HER2-Positive Breast Cancer Revenue by Type (2021-2026) & (USD Million)

Table 89. Europe HER2-Positive Breast Cancer Revenue by Application (2016-2021) & (USD Million)

Table 90. Europe HER2-Positive Breast Cancer Revenue by Application (2021-2026) & (USD Million)

Table 91. Europe HER2-Positive Breast Cancer Revenue by Country (2016-2021) & (USD Million)

Table 92. Europe HER2-Positive Breast Cancer Revenue by Country (2021-2026) & (USD Million)

Table 93. Asia-Pacific HER2-Positive Breast Cancer Revenue by Type (2016-2021) & (USD Million)

Table 94. Asia-Pacific HER2-Positive Breast Cancer Revenue by Type (2021-2026) & (USD Million)

Table 95. Asia-Pacific HER2-Positive Breast Cancer Revenue by Application (2016-2021) & (USD Million)

Table 96. Asia-Pacific HER2-Positive Breast Cancer Revenue by Application (2021-2026) & (USD Million)

Table 97. Asia-Pacific HER2-Positive Breast Cancer Revenue by Region (2016-2021) & (USD Million)

Table 98. Asia-Pacific HER2-Positive Breast Cancer Revenue by Region (2021-2026) & (USD Million)

Table 99. South America HER2-Positive Breast Cancer Revenue by Type (2016-2021) & (USD Million)

Table 100. South America HER2-Positive Breast Cancer Revenue by Type (2021-2026) & (USD Million)

Table 101. South America HER2-Positive Breast Cancer Revenue by Application (2016-2021) & (USD Million)

Table 102. South America HER2-Positive Breast Cancer Revenue by Application (2021-2026) & (USD Million)

Table 103. South America HER2-Positive Breast Cancer Revenue by Country (2016-2021) & (USD Million)

Table 104. South America HER2-Positive Breast Cancer Revenue by Country (2021-2026) & (USD Million)

Table 105. Middle East & Africa HER2-Positive Breast Cancer Revenue by Type (2016-2021) & (USD Million)

Table 106. Middle East & Africa HER2-Positive Breast Cancer Revenue by Type (2021-2026) & (USD Million)

Table 107. Middle East & Africa HER2-Positive Breast Cancer Revenue by Application (2016-2021) & (USD Million)

Table 108. Middle East & Africa HER2-Positive Breast Cancer Revenue by Application (2021-2026) & (USD Million)

Table 109. Middle East & Africa HER2-Positive Breast Cancer Revenue by Country (2016-2021) & (USD Million)

Table 110. Middle East & Africa HER2-Positive Breast Cancer Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. HER2-Positive Breast Cancer Picture

Figure 2. Global HER2-Positive Breast Cancer Revenue Market Share by Type in 2020

Figure 3. Grifola Frondosa

Figure 4. Surgery

Figure 5. Radiation and Chemotherapy

Figure 6. Endocrine Therapy

Figure 7. Molecular Targeted Therapy

Figure 8. HER2-Positive Breast Cancer Revenue Market Share by Application in 2020

Figure 9. Hospital Picture

Figure 10. Specialist Clinic Picture

Figure 11. Biotechnology and Pharmaceutical Companies Picture

Figure 12. Research and Academic Institutions Picture

Figure 13. Other Picture

Figure 14. Global HER2-Positive Breast Cancer Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 15. Global HER2-Positive Breast Cancer Revenue and Forecast (2016-2026) & (USD Million)

Figure 16. Global HER2-Positive Breast Cancer Revenue Market Share by Region (2016-2026)

Figure 17. Global HER2-Positive Breast Cancer Revenue Market Share by Region in 2020

Figure 18. North America HER2-Positive Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Europe HER2-Positive Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Asia-Pacific HER2-Positive Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)

Figure 21. South America HER2-Positive Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)

Figure 22. Middle East and Africa HER2-Positive Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)

Figure 23. HER2-Positive Breast Cancer Market Drivers

Figure 24. HER2-Positive Breast Cancer Market Restraints

Figure 25. HER2-Positive Breast Cancer Market Trends

Figure 26. Pfizer (Pharmacia and Upjohn Company) Recent Developments and Future Plans

Figure 27. Novartis Recent Developments and Future Plans

Figure 28. AstraZeneca Pharmaceuticals Recent Developments and Future Plans

Figure 29. Eli Lilly Recent Developments and Future Plans

Figure 30. Roche Group Recent Developments and Future Plans

Figure 31. Merck Recent Developments and Future Plans

Figure 32. Jiangsu HengRui Medicine Recent Developments and Future Plans

Figure 33. Odonate Therapeutics Recent Developments and Future Plans

Figure 34. Radius Pharmaceuticals Recent Developments and Future Plans

Figure 35. Immunomedics Recent Developments and Future Plans

Figure 36. Syndax Pharmaceuticals Recent Developments and Future Plans

Figure 37. Bayer Recent Developments and Future Plans

Figure 38. Eagle Pharmaceuticals Recent Developments and Future Plans

Figure 39. Merrimack Pharmaceuticals Recent Developments and Future Plans

Figure 40. GlaxoSmithKline Recent Developments and Future Plans

Figure 41. Millennium Pharmaceuticals Recent Developments and Future Plans

Figure 42. Global HER2-Positive Breast Cancer Revenue Share by Players in 2020

Figure 43. HER2-Positive Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 44. Global Top 3 Players HER2-Positive Breast Cancer Revenue Market Share in 2020

Figure 45. Global Top 10 Players HER2-Positive Breast Cancer Revenue Market Share in 2020

Figure 46. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 47. Global HER2-Positive Breast Cancer Revenue Share by Type in 2020

Figure 48. Global HER2-Positive Breast Cancer Market Share Forecast by Type (2021-2026)

Figure 49. Global HER2-Positive Breast Cancer Revenue Share by Application in 2020

Figure 50. Global HER2-Positive Breast Cancer Market Share Forecast by Application (2021-2026)

Figure 51. North America HER2-Positive Breast Cancer Sales Market Share by Type (2016-2026)

Figure 52. North America HER2-Positive Breast Cancer Sales Market Share by Application (2016-2026)

Figure 53. North America HER2-Positive Breast Cancer Revenue Market Share by Country (2016-2026)

Figure 54. United States HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. Canada HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 56. Mexico HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 57. Europe HER2-Positive Breast Cancer Sales Market Share by Type (2016-2026)

Figure 58. Europe HER2-Positive Breast Cancer Sales Market Share by Application (2016-2026)

Figure 59. Europe HER2-Positive Breast Cancer Revenue Market Share by Country (2016-2026)

Figure 60. Germany HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. France HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. United Kingdom HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. Russia HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. Italy HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 65. Asia-Pacific HER2-Positive Breast Cancer Sales Market Share by Type (2016-2026)

Figure 66. Asia-Pacific HER2-Positive Breast Cancer Sales Market Share by Application (2016-2026)

Figure 67. Asia-Pacific HER2-Positive Breast Cancer Revenue Market Share by Region (2016-2026)

Figure 68. China HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. Japan HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 70. South Korea HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. India HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 72. Southeast Asia HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 73. Australia HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 74. South America HER2-Positive Breast Cancer Sales Market Share by Type (2016-2026)

Figure 75. South America HER2-Positive Breast Cancer Sales Market Share by Application (2016-2026)

Figure 76. South America HER2-Positive Breast Cancer Revenue Market Share by Country (2016-2026)

Figure 77. Brazil HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 78. Argentina HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 79. Middle East and Africa HER2-Positive Breast Cancer Sales Market Share by Type (2016-2026)

Figure 80. Middle East and Africa HER2-Positive Breast Cancer Sales Market Share by Application (2016-2026)

Figure 81. Middle East and Africa HER2-Positive Breast Cancer Revenue Market Share by Country (2016-2026)

Figure 82. Turkey HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 83. Saudi Arabia HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 84. UAE HER2-Positive Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 85. Methodology

Figure 86. Research Process and Data Source